XML 91 R46.htm IDEA: XBRL DOCUMENT v3.22.4
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2022
Segment Reporting [Abstract]  
Sales of Company's Products
Sales of the Company’s products were as follows:
Years Ended December 31202220212020
U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$12,686 $8,251 $20,937 $9,765 $7,421 $17,186 $8,352 $6,028 $14,380 
Alliance revenue - Lynparza (1)
584 532 1,116 515 473 989 417 308 725 
Alliance revenue - Lenvima (1)
579 297 876 417 287 704 359 220 580 
Alliance revenue - Reblozyl (2)
123 43 166 — 17 17 — — — 
Vaccines
Gardasil/Gardasil 9
2,065 4,832 6,897 1,881 3,792 5,673 1,755 2,184 3,938 
ProQuad/M-M-R II/Varivax1,724 518 2,241 1,629 506 2,135 1,378 500 1,878 
RotaTeq508 275 783 473 334 807 486 311 797 
Pneumovax 23
346 256 602 547 346 893 727 359 1,087 
Vaqta95 78 173 100 79 179 103 67 170 
Hospital Acute Care
Bridion922 762 1,685 762 770 1,532 583 615 1,198 
Prevymis188 240 428 153 218 370 119 162 281 
Dificid241 22 263 166 10 175 102 7 110 
Primaxin1 238 239 2 258 259 2 248 251 
Noxafil51 187 238 60 199 259 42 287 329 
Invanz4 185 189 (5)207 202 9 202 211 
Cancidas6 168 174 4 208 212 7 207 213 
Zerbaxa89 79 169 4 (5)(1)74 56 130 
Cardiovascular
Alliance revenue - Adempas/Verquvo (3)
329 12 341 312 30 342 259 22 281 
Adempas— 238 238 — 252 252 — 220 220 
Virology
Lagevrio1,523 4,161 5,684 632 320 952 — — — 
Isentress/Isentress HD274 359 633 294 474 769 326 531 857 
Neuroscience
Belsomra79 179 258 78 241 318 81 247 327 
Immunology
Simponi— 706 706 — 825 825 — 838 838 
Remicade— 207 207 — 299 299 — 330 330 
Diabetes
Januvia1,248 1,565 2,813 1,404 1,920 3,324 1,470 1,836 3,306 
Janumet355 1,344 1,700 367 1,597 1,964 477 1,494 1,971 
Other pharmaceutical (4)
969 1,282 2,249 841 1,275 2,118 882 1,321 2,202 
Total Pharmaceutical segment sales24,989 27,016 52,005 20,401 22,353 42,754 18,010 18,600 36,610 
Animal Health:
Livestock710 2,590 3,300 667 2,628 3,295 612 2,327 2,939 
Companion Animals1,112 1,138 2,250 1,091 1,182 2,273 872 892 1,764 
Total Animal Health segment sales1,822 3,728 5,550 1,758 3,810 5,568 1,484 3,219 4,703 
Other segment sales (5)
— — — — — — 23 — 23 
Total segment sales26,811 30,744 57,555 22,159 26,163 48,322 19,517 21,819 41,336 
Other (6)
395 1,333 1,728 266 116 382 71 111 182 
 $27,206 $32,077 $59,283 $22,425 $26,279 $48,704 $19,588 $21,930 $41,518 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 5).
(2)    Alliance revenue for Reblozyl represents royalties and, for 2022, also includes a payment received related to the achievement of a regulatory approval milestone (see Note 5).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 5).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were fully divested by the first quarter of 2020.
(6)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities which increased (decreased) sales by $810 million, $(203) million and $(19) million in 2022, 2021 and 2020, respectively, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for 2022, 2021 and 2020 also includes $165 million, $218 million and $54 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Revenues by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Years Ended December 31202220212020
United States$27,206 $22,425 $19,588 
Europe, Middle East and Africa14,493 13,341 11,547 
China5,191 4,378 2,751 
Japan3,629 2,726 2,602 
Asia Pacific (other than China and Japan)3,614 2,407 2,113 
Latin America2,582 2,206 1,890 
Other2,568 1,221 1,027 
 $59,283 $48,704 $41,518 
Reconciliation of Segment Profits to Income Before Taxes
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
Years Ended December 31202220212020
Segment profits:
Pharmaceutical segment$36,852 $30,977 $26,106 
Animal Health segment1,963 1,950 1,669 
Other segments— — 1 
Total segment profits38,815 32,927 27,776 
Other profits1,160 156 75 
Unallocated:
Interest income157 36 59 
Interest expense(962)(806)(831)
Amortization(2,085)(1,636)(1,817)
Depreciation(1,642)(1,414)(1,519)
Research and development(13,011)(11,692)(12,911)
Restructuring costs(337)(661)(575)
Other unallocated, net(5,651)(3,031)(4,394)
$16,444 $13,879 $5,863 
Equity Loss from Affiliates and Depreciation Included in Segment Profits
Equity income/loss from affiliates and depreciation included in segment profits is as follows:
PharmaceuticalAnimal HealthAll OtherTotal
Year Ended December 31, 2022      
Included in segment profits:
Equity income from affiliates$39 $— $— $39 
Depreciation5 177 — 182 
Year Ended December 31, 2021      
Included in segment profits:
Equity income from affiliates$11 $— $— $11 
Depreciation6 158 — 164 
Year Ended December 31, 2020      
Included in segment profits:
Equity loss from affiliates$6 $— $— $6 
Depreciation6 143 1 150 
Property, Plant and Equipment, Net by Geographic Area
Property, plant and equipment, net, by geographic area where located is as follows:
December 31202220212020
United States$12,891 $11,759 $10,394 
Europe, Middle East and Africa6,993 6,081 5,314 
Asia Pacific (other than China and Japan)966 857 737 
Latin America225 199 169 
China207 220 216 
Japan135 159 166 
Other5 4 4 
 $21,422 $19,279 $17,000